Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate in development for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhibitor, RDEA684, is currently in preclinical development. RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK), is being developed under a global license agreement with Bayer HealthCare AG. RDEA119 is currently being evaluated in advanced cancer patients with different tumor types as a single agent in a Phase 1 study, as well as in combination with sorafenib (Nexavar®, Bayer HealthCare, Onyx Pharmaceuticals, Inc.) in a Phase 1/2 study. RDEA806, for the treatment of HIV, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has successfully completed a Phase 2a study in HIV patients. RDEA427, a next generation NNRTI, has superior pharmacokinetic properties, and even greater activity against a wide range of drug-resistant viral isolates than RDEA806. We have evaluated RDEA427 in a human micro-dose pharmacokinetic study.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" with
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 The global ... 49.12 billion by 2020, growing at a CAGR of ... report by Grand View Research, Inc. Monitoring services is ... from 2014 to 2020.      (Logo: ... with rising incidences of chronic diseases such as cancer, ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
(Date:8/27/2015)... 27, 2015 Biosimilars are not generics ... U.S. Food and Drug Administration (FDA) for recognizing ... its draft guidance issued today. The FDA,s draft ... distinguishable names, calling for biological products to bear ... This proposal reflects the agency,s thinking that "there ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... -- At this very moment, FIRMOO is being heatedly discussed ... eyeglasses from FIRMOO are being delivered to various countries of ... so many eyeglasses wearers? In this brand new year of ... platforms, is giving away thousands of free eyeglasses every day ...
... 6, 2012 ViroPharma Incorporated (NASDAQ: ... HALO ) today announced the presentation of positive ... Cinryze® (C1 esterase inhibitor [human]) in combination with ... using Halozyme,s recombinant human hyaluronidase enzyme (rHuPH20), in ...
Cached Medicine Technology:Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 2Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 3ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 2ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 3ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 4ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 5ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 6ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 7ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20) 8
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... announced a back to school special. The company is currently offering lice head checks ... In addition, the company is offering a 10% discount on their lice treatment products. ...
(Date:8/30/2015)... ... 30, 2015 , ... Certified Nutrition Businessman Reid Eckert agrees to extend his ... is a global sales and communications firm that offers U.S. brands a proven path ... relationship with Mr. Reid Eckert, as his interpretation of the nutritional needs of the ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President ... the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served ... college expand its reach and impact through innovative technologies and strategies. , “I am ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... , ... Brands like Toppik , Eau Thermale Avene and Bliss are ... threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, ... for customers regardless of the item’s selling price.” , With competitive pricing in the ...
Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Marketing brand leaders are,increasingly finding value in the ... and in particular in use of the on-demand ... http://www.BestPracticeDatabase.com ). Although documents from the database ... have come to,find outstanding value in membership to ...
... Canadian Cancer Society shows that many cancer survivors in ... at risk for health problems, including their cancer returning. ... to look at ways to better support cancer survivors ... body weight, says Dr. Kerry Courneya, professor and Canada ...
... about the disease, researchers discover , , SUNDAY, April 20 ... wrenching, especially for family members of the patient. , ... blacks, are more likely to labor under misconceptions about ... part of aging, researchers are learning. , And that ...
... excess weight, , , SATURDAY, April 19 (HealthDay News) -- Pregnancy ... After all, a pregnant woman has to nourish two bodies ... is, the baby,s nutritional needs are only around 300 calories ... of pregnancy complications for both mother and child. , And, ...
... Free Playtex(R) Drop-Ins(R) Original Nurser Systems, WESTPORT, ... division of Energizer(R) Personal Care, the leader in ... in baby bottles by,announcing it will distribute one ... which are free of bisphenol A, a,chemical used ...
... of,Pediatrics (AAP) highlights the importance and success of ... Vaccines,have eliminated or reduced many of the most ... the nation,s public health efforts., According to ... immunization:, -- Over 13,000 people in the ...
Cached Medicine News:Health News:Best Practice Database Provides Exceptional Value to Marketing Executives 2Health News:Obesity, inactivity as common among cancer survivors as rest of Canadians, study shows 2Health News:Obesity, inactivity as common among cancer survivors as rest of Canadians, study shows 3Health News:Filling in the Alzheimer's 'Race Gap' 2Health News:Filling in the Alzheimer's 'Race Gap' 3Health News:Extra Pounds During and Between Pregnancies Can Pose Problems 2Health News:Extra Pounds During and Between Pregnancies Can Pose Problems 3Health News:Playtex(R) Offers Free Non-BPA Baby Bottles to Parents, Will Stop Using BPA in All Products This Year 2Health News:AAP Encourages Parents to Immunize Their Children 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: